Targets:EROL

Layout Table~~~~1506~1506~~

Kinase Screening & Profiling Trends~
Published by HTStec Limited, May 2008

This market report summarizes the results of HTStec’s third global pharma and biotech web-based benchmarking survey on kinase screening and profiling carried out in May 2008.~
Published by HTStec Limited, May 2008

This market report summarizes the results of HTStec’s third global pharma and biotech web-based benchmarking survey on kinase screening and profiling carried out in May 2008.

The objective was to document current practices and preference in kinase screening and profiling, and to understand future user requirements particularly with respect to the need for outsourced services. The aim was to compile a reference document which could be directly compared relative to HTStec’s 2006 report.

The survey looked at in house and oursourced kinase screening and profiling, as practiced in 2008 and predicted for 2010. The following areas were investigated amongst others – therapeutic areas using kinase assays; kinase panel profiling approach, preferred kinase profiling assay technology, technology supplier and outsourced fee for service providers; kinases as a % of R & D spend; interest and requirements for outsourcing kinase primary screening; size of the kinase panels used; use of different tyrosine kinase assay conditions; use of different species variants of kinases; features of a kinase platform of greatest interest to respondents and where kinase service providers should prioritize going forward.

Table Of Contents~Kinase Screening & Profiling Trends 2008 Market Report (Electronic Site Licence)|1223|~1506~3398~~

Cancer Stem Cells - Emerging Therapeutic, Diagnostic and Market Opportunities~
Published by BioPharm Reports, January 2008

This report gives a comprehensive up-to-date review of global R&D on CSCs and strategies to target them. This includes around 30 companies or commercially based research organisations (including 20 SMEs and five major pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, current clinical trials and related areas. Also covered are current developments on the detection of CSCs and new diagnostic approaches. Commercial opportunities in drug discovery and diagnostics relating to CSCs are also presented. More than 50 academic research teams from 13 different countries are reviewed, together with leading discoveries in this field. Current patents referring to CSCs (70+ by Dec 2007) are also presented.~Published by BioPharm Reports, January 2008

Overview
Tumours and haematological cancers contain small populations of cells that are believed to play a critical role in the progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreas, colon, brain and lung cancers. It is thought that CSCs are critically involved in the development and metastatic spread of cancer. CSCs have also demonstrated resistance to a number of conventional therapies and it is thought that that this explains why it is difficult to completely eradicate the disease and why recurrence is an ever-present threat. If these findings are now confirmed in the clinic, the selective targeting of CSCs will offer a new paradigm in both cancer therapeutics and diagnostics. Currently there are more than 30 CSC R&D programmes in progress, around 50% of which are at Phase I or beyond. Patient data from the first clinical trials of drugs believed to target CSCs, are now being reported. Most CSC R&D programmes are being taken forward by SME's and > 90% of the 70 patents in this area (which more than doubled in 2007) have been filed by Universities. Substantial opportunity for collaboration is this field has recently lead to agreements between SMEs and major pharmaceutical companies. This includes a recent announcement of a collaboration between GSK and Oncomed Pharmaceuticals, Inc.

Drug Discovery and Pipeline/b>

More than ten different strategies are being actively researched to enable the selective therapeutic targeting of CSCs, which are described in this report. In December 2007, clinical data were reported on GSK's Tykerb (which is already approved in the US for breast cancer), that targets the CD44+/CD24+ population of breast cancer cells i.e. breast CSCs. ChemGenix has also recently published clinical data from a Phase II/III CML clinical trial of omacetaxine mepesuccinate, which is believed to target CSCs. Stemline Therapeutics have reported that their investigational CSC-targeting molecule SL-401, has demonstrated single agent anti-tumour activity in acute myeloid leukaemia in a multi-centre Phase I/II dose escalation study. Currently around 30 companies or commercially based research organisations are progressing R&D activities in the CSC field, 65% of which are SME's. This report identifies five "Top-25" pharmaceutical companies that are progressing developments relating to CSCs. Of the current 30 R&D programmes, around 50% are at Phase I or beyond. The availability of isolated CSCs to drug discovery companies offers opportunities to identify new druggable targets and to re-examine existing drug libraries that have not been screened against this unique subset of cells, or xenograft models developed from them.

Cancer Diagnostics

CSCs are believed to be causally linked to the development and metastatic spread of cancer. If this is confirmed in man, this will likely place CSCs at the heart of cancer diagnostics. Researchers have identified a number of surface proteins such as CD44, CD133 and many others, which may have important application as biomarkers and diagnostics. Some of these surface proteins are found on a number of different CSCs, whereas others appear to be unique to certain CSCs. A number of intracellular markers found in CSCs, may also have diagnostic utility. These developments are described in this report. CD133 mRNA levels in peripheral blood, measured using RT-PCR, have been found to predict colon cancer recurrence. There is a need for new methodologies that isolate and characterise circulating tumour cells (CTCs) in the blood, that can be applied to CSCs. CTC technologies using the EpCam marker to isolate these cells are able to predict colon cancer recurrence. The adaption of these techniques based on specific CSC phenotypes may provide sensitive new methods for identifying CSCs in the body. Innovation in advanced microfluidic, chip-based and genetic/phenotypic screening technologies are anticipated in the future. OncoMed Pharmaceuticals have announced the discovery of a gene expression profile of CSCs (breast and other cancers), that correlate with clinical outcome.

Table of Contents~Single user license PDF|1012|Two user licenses PDF|1013|Three user licenses PDF|1014|Four user licenses PDF|1015|Five - 99 user licenses|1016|~1506~3310~~

Peripheral Neuropathy and Neuropathic Pain, 2008~
Published by BioPharm Reports, January 2008

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants).~Published by BioPharm Reports, January 2008

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants). This report gives a comprehensive update on all current drugs, together with the entire drug development pipeline, from pre-clinical through to Phase III, Registration and initial Launch. The pipeline includes 80 candidates being developed to treat PN and NP as a primary indication and 60 "second-indication" drugs. More than 300 patents published in the PN and NP field between 2002 and 2007 have also been assessed and presented, together with the identification of potential candidate molecules and drug targets which have not entered the development pipeline, but which may do so in the future. This report was written to provide a comprehensive update on therapeutic developments relating to PN and NP, both in tackling its most serious and debilitating symptoms, but also in targeting and potentially correcting the underlying disease mechanisms. Commercial evaluation and assessments including markets, market size, market sectors, sales and trends relating to PN and NP are also included in this report.

Drug Targets

Most current and developmental therapies for neuropathic conditions are directed at NP. Moreover, many of today's commonly used drugs in this area were developed for other indications, but subsequently were found to offer useful application in the treatment of NP. These include anticonvulsants, antidepressants and others. These "second indication" drugs represent around 10 pharmacological mechanisms including 5 hydroxytryptamine uptake inhibitors, cannabinoid CB1 agonists, carnitine acetyltransferase stimulants, GABA receptor agonists, NMDA antagonist, opioid mu receptor agonists, sodium channel antagonists, tumour necrosis factor alpha antagonists and others of unidentified pharmacological activity. In contrast, only a few molecules have been developed specifically for NP as a primary indication and these include an aldose reductase inhibitor, a membrane integrity agonist and an opioid kappa receptor agonist. However, the last ten years have seen important advances in the understanding of peripheral neuropathy and neuropathic pain at the biological and pathophysiological level and this is reflected in the numbers of new candidates in the drug development pipeline. Today, there are more than 40 drug types in development for the treatment of PN or NP as primary indications, more than 30 of which are directed at new drug targets. Whilst most of these are directed at NP, a number are targeting the underlying disease mechanisms, offering the hope that NP disease progression may be blocked or even reversed. The development and extension of new and existing molecules for the treatment of NP and PN as second indication drugs continues, and collectively these two groups (i.e. primary + secondary indication drugs) represent over 60 different drug types. Recent patent filings, 2002-2007, show a significant number of other therapeutic opportunities which have not entered the drug development pipeline, but which may do so in the future. This report identifies these candidates on the basis of their mechanism of action, drug target, developmental stage, by company and other relevant areas.

Background and Questions

PN and NP are causally linked to a number of conditions including diabetes, auto immunity, infection, cancer, drugs or toxins, the autonomic nervous system and hereditary diseases. It is estimated in this report that PN and NP currently affect 170 to 270 million individuals globally, figures that are set to increase by more than 10% by 2012. This report discusses the major peripheral neuropathies as well as neuropathic pain, together with prevalence, trends and treatments. Some of the questions considered in this report include:

which therapies are available for the treatment of PN and NP, their capabilities and failings, unmet need
What is happening in the developments pipeline, which candidates are nearest to market
what are the prevalences of the major neuropathies and what are the future anticipated trends
what strategies are being developed in the treatment of PN and NP, prospects of success and failure
which companies are developing new therapies for PN and NP
what are the current market sizes relating to PN and NP, including market sectors, sales and anticipated growth over the next 5 years

Report Contents~Peripheral Neuropathy and Neuropathic Pain, 2008 (PDF)|1111|~1506~3301~~

Kinase Screening Profiling Trends 2006~
Published by HTStec, September 2006

This market report summarizes the results of the second industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling. The objective of this study was to document current practices and preferences and to understand future user requirements (particularly in respect of the need for outsourced services) in kinase screening and profiling.

The survey looked at various points including in-house and outsourced kinase screening and profiling as practiced in 2006 and predicted for 2007 and 2008. The following specific areas were investigated : therapeutic areas using kinase assays, kinase panel profiling approach; preferred assay technology, supplier and outsourced fee-for-service providers; kinase profiling budgets and breakdown; interest in label free assays, multiplexed methods of kinase profiling and cell-based approaches for signaling pathway analysis of kinase inhibitors and features of a new kinase platform of greatest interest to respondents.~Published by HTStec, September 2006

This market report summarizes the results of the second industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling. The objective of this study was to document current practices and preferences and to understand future user requirements (particularly in respect of the need for outsourced services) in kinase screening and profiling.

The survey looked at various points including in-house and outsourced kinase screening and profiling as practiced in 2006 and predicted for 2007 and 2008. The following specific areas were investigated : therapeutic areas using kinase assays, kinase panel profiling approach; preferred assay technology, supplier and outsourced fee-for-service providers; kinase profiling budgets and breakdown; interest in label free assays, multiplexed methods of kinase profiling and cell-based approaches for signaling pathway analysis of kinase inhibitors and features of a new kinase platform of greatest interest to respondents.

Table of contents

~Kinase Screening Profiling Trends 2006 (PDF)|749|~1506~2683~~

GPCR Assay Trends~
Published by HTStec, September 2005

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.~Untitled Document
Published by HTStec, September 2005

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.

Highlights of this Report:

• The survey collected 63 responses (52 complete and 11 partially filled out) from 48 different Pharma/Biotech companies.
• Responses were split geographically 43% North America and 57% Europe.
• Survey respondents were drawn from 27 Large Pharma, 33 Small Pharma/Biotechs, 1 Large Agro Company, Baby and Clinical Nutrition Company and 1 Pharma-Linked Research Organization.
• Survey respondents represented 27 primary screening (HTS) labs, 15 assay development labs, 12 secondary screening/hits-toleads (lead optimization) labs, 2 therapeutic area labs, 1 compound profiling lab and 6 other lab functions.
• Survey results were expressed as an industry average of all respondents. In addition, all results were fully reanalyzed after subdivision into the following survey groups: 1) by organization type - Large Pharma; 2) by organization type - Small Pharma/Biotech; 3) by geographic location - North America and 4) by geographic location – Europe.
• The mean number of primary GPCR screens undertaken in 2004 was estimated to be 7.1 screens per year with 489K wells (data points) per screen.
• Globally it was estimated that 1533 GPCR primary screens campaigns will be performed in 2004, 71% will be cell-based and 6% orphans.
• The Pharma market for GPCR primary screening reagents was estimated to be US$70Million in 2004, with an annual growth rate of 26%.
• The preferred approaches to GPCR profiling were to either to screen selected lead compounds in house against a GPCR panel or to outsource screening of selected lead compounds to a fee-for-service GPCR panel provider.
• The Pharma market for GPCR profiling was estimated in 2004 to be US$37.6Million and US$36.2Million for in house and outsourced profiling respectively.
• About 8X more data points were profiled against GPCRs in house versus outsourced in 2004.
• The mean budget allocated per lab for GPCR profiling in 2004 was estimated to be US$175K in house versus US$168K for outsourced profiling.
• The mean price per data point for GPCR profiling was estimated to be US$4.30 in house versus US$35.42 for outsourced.
• The mean number of FTEs supporting in house GPCR screening and profiling was 5.4 and 2.8 FTEs/lab respectively.

Table of Contents

~GPCR Assay Trends (PDF)|775|~1506~2620~~

Tissue Microarrays~
Published by Select Biosciences, May 2004

The report provides in-depth information on the market and size segmented by technology and application. In addition to a detailed market model, Tissue Microarrays : Market Assessment and Opportunities evaluates the strengths and weaknesses of each of the TMA vendors, and assesses both opportunities and threats facing their products & services. The companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward are identified.
~Published by Select Biosciences, May 2004

The report provides in-depth information on the market and size segmented by technology and application. In addition to a detailed market model, Tissue Microarrays : Market Assessment and Opportunities evaluates the strengths and weaknesses of each of the TMA vendors, and assesses both opportunities and threats facing their products & services. The companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward are identified.

View Full Table of Contents~Tissue Microarrays%3A Full Report - Single user print version|48|Tissue Microarrays%3A Full Report - PDF site License +1 print copy|621|~1506~2471~~
Menu Page | Toolbar Page |
Frameset Page | Index Page | Table of Contents
EROL - Electronic Retail Online E-commerce shopping cart software